Rise Above Typical Expectations: Mounjaro 2

Classes Diabetes Rise Above Typical Expectations: Mounjaro 2


Please Sign in to your account to see the Class.


In this video, you will explore more about how Mounjaro (Tirezapetide) helped people with Type 2 Diabetes Mellitus in SURPASS-3 Trail.

SURPASS-3: a 52-weeks, randomized, open-label, phase 3 trial, comparing Mounjaro vs Insulin Degludec 100 U/ml in 1444 adults with T2DM inadequately controlled on metformin with or without SGLT-2.


This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: [email protected]
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

Please go to PDF Material for prescribing information